WEBULL
WebtradeDownload

Is BioLife Solutions (BLFS) Fairly Valued As Repligen Buys It Out?

Simply Wall St · 2d ago

BioLife Solutions (BLFS) has officially been acquired by Repligen in a cash and stock deal valued at about $1.6 billion. This transaction effectively ends BioLife’s status as an independent, publicly traded company.

At a latest share price of $38.61, BioLife Solutions has seen a 1-month share price return of 9.53% and a 90-day share price return of 36.77%, while the 3-year total shareholder return of 196.77% points to powerful long haul compounding that the Repligen buyout has effectively crystallised for existing investors.

Spot similar potential to the BioLife Solutions deal by scanning our curated list of 19 high quality undiscovered gems across the broader cell and gene therapy ecosystem and adjacent life science tools.

BioLife Solutions clearly built a valuable niche in cell and gene therapy tools. The open question now is whether the US$31 per share deal price fairly reflects that strength.

Price-to-Earnings of 38.4x: Is it justified?

BioLife Solutions now trades at a P/E of 38.4x, which prices the stock above the SWS fair P/E estimate but roughly in line with global life sciences peers.

The P/E ratio compares the current share price with earnings per share. For a specialist bioproduction supplier like BioLife Solutions, that multiple effectively reflects what investors are willing to pay today for each dollar of profit generated from its cell and gene therapy tools platform.

BioLife Solutions is considered expensive versus the estimated fair P/E of 15x, which points to a rich premium on current earnings. At the same time, the multiple is below the broader life sciences industry average of 42.2x and close to the global life sciences norm of 38.8x. This suggests that the market is valuing the business in line with many comparable stocks even after the Repligen deal.

Explore the SWS fair ratio for BioLife Solutions.

Result: Price-to-Earnings of 38.4x (OVERVALUED)

Still, BioLife Solutions faces real risks if cell and gene therapy demand slows or rival bioproduction suppliers pressure pricing and compress the current valuation premium.

Find out about the key risks to this BioLife Solutions narrative.

Another View on BioLife Solutions Using DCF

The P/E workup presents BioLife Solutions as expensive, yet our DCF model points to a value of about $37.30 per share versus the current $38.61 price. That suggests the stock is slightly overvalued based on cash flows, which raises the question of which lens to rely on for a deal already on the table.

Look into how the SWS DCF model arrives at its fair value.

BLFS Discounted Cash Flow as at Oct 2026
BLFS Discounted Cash Flow as at Oct 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out BioLife Solutions for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 27 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Sentiment around BioLife Solutions is mixed in this deal, so consider reviewing the underlying numbers promptly and forming your own view of its potential upside. To see what investors are optimistic about in the profile, review the 3 key rewards.

Looking for more investment ideas beyond BioLife Solutions?

If BioLife Solutions has you thinking about what else might be hiding in plain sight, use this moment to line up your next set of opportunities before the crowd catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.